动物造模 中国实验动物信息网 2023-08-03 900

　　Objective To verify the delayed effect of Bevacizumab injection on wound healing of cynomolgus monkeys by observing the effect of Bevacizumab injection on the speed of wound healing of the back skin of cynomolgus monkeys and the expression of CD34 in the injured skin tissue, and to provide a dose and frequency reference for clinical tumor surgery patients when using Bevacizumab for treatment.

　　Methods Six male cynomolgus monkeys were used to establish a wound healing evaluation model by full back skin excision. Three cynomolgus monkeys were randomly selected as the normal saline group, and the other three cynomolgus monkeys were selected as the Bevacizumab group. The cynomolgus monkeys in the Bevacizumab group were injected with 30 mg/kg Bevacizumab injection intravenously at 0,4,8,11 days after surgery, and the normal saline group were injected with the same amount of normal saline intravenously; After surgery, blood routine tests were performed and the wound healing status of each group of crab eating monkeys was observed. Image J software was used to analyze the wound healing rate and evaluate the severity of the wound condition using a scoring method. After 4 weeks, skin samples were taken from 6 crab eating macaques for wound healing, and the expression level of CD34 in the skin tissue was examined using immunohistochemistry.

　　The result was a successful construction of a wound healing evaluation model for crab eating monkeys. On the 3rd day after surgery, the number of white blood cells and neutrophils in the blood of the crab eating monkey significantly increased (P<0.05). On the 7th day, the number of white blood cells gradually returned to normal, while there were no significant changes in red blood cells, hemoglobin, and hematocrit, indicating that the animal's nutritional status was good. Compared with the normal saline group, the wound healing rate in the Bevacizumab group was significantly lower at 7 and 28 days after surgery (P<0.01, P<0.001), and the expression level of CD34 in the healing skin tissue was significantly lower (P<0.01).

　　Conclusion The injection of Bevacizumab may delay wound healing by inhibiting the angiogenesis in the new skin tissue of cynomolgus monkeys. In clinical practice, when patients use Bevacizumab injection after surgery, the advantages and disadvantages should be weighed, and the intervention time, dose and frequency should be scientifically and reasonably selected.